Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharma (PCRX) Reports In-Line Q1 EPS
May 3, 2018 8:06 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $73.69 million.
Pacira reiterated its full year 2018 financial guidanceFor earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More